Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT01266447 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
27
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)

Collaborators